Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Combined With SOX in Perioperative Treatment of Locally Advanced Gastric and GEJ Adenocarcinoma
NCT05739045Phase 2Recruiting
- Start
- Nov 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. Primary endpoint: Pathological Complete Response Rate at 3 months. Started Nov 2022; status: recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT05739045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05739045.